Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 12, 2004, Pages 1286-1293

  Bolton, Charlotte E ^b   Ionescu, Alina A ^b   Shiels, Kathleen M ^b   Pettit, Rebecca J ^b   Edwards, Peter H ^b   Stone, Michael D ^b   Nixon, Lisette S ^b   Evans, William D ^b   Griffiths, Timothy L ^b   Shale, Dennis J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Body composition; Dual energy X ray absorptiometry; Osteoporosis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CELL PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PSEUDOURIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DENSITY; BONE MINERAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLLAGEN METABOLISM; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BODY COMPOSITION; BONE DENSITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 10644288504     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200406-754OC     Document Type: Article

References (64)

1. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;139:1435-1438.
2. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:961-966.
3. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856-1861.
4. Schols AMWJ, Soeters PB, Dingemans AMC, Mostert R, Frantzen PJ, Wouters EFM. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-1156.
5. Shoup R, Dalsky G, Warner S, Davies M, Connors M, Khan M, Khan F, ZuWallack R. Body composition and health-related quality of life in patients ith obstructive airways disease. Eur Respir J 1997;10:1576-1580.
6. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Niewoehner DE. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704-709.
7. Edelstein SL, Barrett-Connor E. Relation between body size and bone mineral density in elderley men and women. Am J Epidemiol 1993;138:160-169.
8. Baumgartner RN, Stauber PM, Koehler KM, Romero L, Garry PJ. Associations of fat and muscle masses with bone mineral in elderly men and women. Am J Clin Nutr 1996;63:365-372.
9. Coin A, Sergi G, Benincà P, Lupoli L, Cinti G, Ferrara L, Benedetti G, Tomasi G, Pisent C, Enzi G. Bone mineral density and body composition in underweight and normal elderly subjects. Osteoporos Int 2000; 11:1043-1050.
10. Incalzi RA, Caradonna P, Ranieri P, Basso S, Fuso L, Pagano F, Ciappi C, Pistelli R. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 2000;94:1079-1084.
11. Bakker I, Twisk JWR, van Mechelen W, Kemper HCG. Fat-free body mass is the most important body composition determinant of 10-year longitudinal development of lumbar bone in adult men and women. J Clin Endocrinol Metab 2003;88:2607-2613.
12. Hunter AMB, Carey MA, Larsh HW. The nutritional status of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1981; 96:556-565.
13. Donahue M, Rogers RM, Wilson DO, Pennock BE. Oxygen consumption of the respiratory muscles in normal and in malnourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;94:1260-1263.
14. Schols AM, Mostert R, Soeters PB, Wouters EF. Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax 1991;46:695-699.
15. Baarends EM, Schols AM, Pannemans DL, Westerterp KR, Wouters EF. Total free living energy expenditure in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155: 549-554.
16. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164: 1414-1418.
17. Debigaré R, Marquis K, Côté CH, Tremblay RR, Michaud A, LeBlanc P, Maltais F. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003;124:83-89.
18. Leech JA, Dullberg C, Kellie S, Pattee L, Gay J. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990;141:68-71.
19. Nishimura Y, Tsutsumi M, Nakata H, Tsunenari T, Maeda H, Yokoyama M. Relationship between respiratory muscle strength and lean body mass in men with COPD. Chest 1995;107:1232-1236.
20. Baarends AM, Schols AMWJ, Mostert R, Wouters EFM. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2807-2813.
21. Visser M, Fuerst T, Lang T, Salamone L, Harris TB, Dual-energy X-ray Absorptiometry and Body Composition Working Group. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass: health, aging and body composition study. J Appl Physiol 1999;87:1513-1520.
22. Steiner MC, Barton RL, Singh SJ, Morgan MD. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J 2002;19:626-631.
23. Engelen MPKJ, Deutz NEP, Wouters EFM, Schols AMWJ. Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1488-1492.
24. Ionescu AA, Nixon LS, Luzio S, Lewis-Jenkins V, Evans WD, Stone MD, Owens DR, Routledge PA, Shale DJ. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. Am J Respir Crit Care Med 2002;165:495-500.
25. Intrieri M, Calcagno G, Oriani G, Pane F, Zarrilli F, Cataldo PT, Foggia M, Piazza M, Salvatore F, Sacchetti L. Pseudouridine and 1-ribosylpyridin-4-one- 3-carboxamide (PCNR) serum concentrations in human immunodeficiency virus type 1-infected patients are independent predictors for AIDS progression. J Infect Dis 1996;174:199-203.
26. Borek EC, Kerr SJ. Atypical transfer RNAs and their origin in neoplastic cells. Adv Cancer Res 1972;15:163-190.
27. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantification of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258.
28. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700.
29. Aris RM, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, Hecker TM, Renner JB, Guillen U, Brown SA, et al. Efficacy of alendronate in cystic fibrosis adults with low bone density. Am J Respir Crit Care Med 2004;169:77-82.
30. Bolton CE, Ionescu AA, Shiels K, Nixon LS, Pettit RJ, Evans WD, Edwards PH, Griffiths TL, Shale DJ. Evidence for cellular and bone connective tissue protein breakdown in patients with COPD [abstract]. Thorax 2003;58(Suppl iii): iii10. S29.
31. Bolton CE, Ionescu AA, Shiels KM, Nixon LS, Pettit RJ, Evans WD, Edwards PH, Linnane SJ, Griffiths TL, Shale DJ. Fat free mass status in patients with COPD [abstract]. Am J Respir Crit Care Med 2004; 169:A615.
32. Bolton CE, Ionescu AA, Shiels KM, Nixon LS, Pettit RJ, Evans WD, Edwards PH, Linnane SJ, Griffiths TL, Shale DJ. Bone loss in patients with chronic obstructive pulmonary disease (COPD) [abstract]. Am J Respir Crit Care Med 2004;169:A616.
33. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLB1/WHO workshop report, 2001. Available at URL http://www.goldcopd.com (accessed October 2004).
34. Fabbri LM, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: 2003 update. Eur Respir J 2003;22:1-2.
35. Blake GM, Wahner HW, Fogelman I. The Evaluation of osteoporosis: dual energy X-ray absorptiometry and ultrasound in clinical practice. London: Martin Dunitz; 1998.
36. Vanltallie TB, Yang MU, Heymsfield SB, Funk RC, Boileau RA. Height-normalised indices of the body's fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr 1990;52:953-959.
37. Bolton CE, Ionescu AA, Evans WD, Pettit RJ, Shale DJ. Altered tissue distribution in adults with cystic fibrosis. Thorax 2003;58:885-889.
38. World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1994. Technical Report Series 843.
39. Li Y, Wang S, Zhong Z. Simultaneous determination of pseudouridine and creatinine in urine of normal children and patients with leukaemia by high performance liquid chromatography. Biomed Chromatogr 1992;6:191-193.
40. Ionescu AA, Chatham K, Davies CA, Nixon LS, Enright S, Shale DJ. Inspiratory muscle function and body composition in cystic fibrosis. Am J Respir Crit Care Med 1998;158:1271-1276.
41. Pouw EM, Schols AM, Deutz NE, Wouters EF. Plasma and amino acid levels in relation to resting energy expenditure and inflammation in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:797-801.
42. Tsujinaka T, Ebisui C, Fujita J, Kishibuchi M, Morimoto T, Ogawa A, Katsume A, Obsugi Y, Kominami E, Monden M. Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Biochem Biophys Res Commun 1995;207:168-174.
43. Li Y-P, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activiation in response to tumour necrosis factor α. FASEB J 1998;12:871-880.
44. Li Y-P, Reid MB. NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000;279:R1165-R1170.
45. Langen RCJ, Schols AMWJ, Kelders MCJM, Wouters EFM, Janssen-Heininger YMW. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-κB. FASEB J 2001;15:1169-1180.
46. Kosmidou I, Vassilakopoulos T, Xagorari A, Zakynthinos S, Papapetropoulos A, Roussos C. Production of interleukin-6 by skeletal myotubes. Am J Respir Cell Mol Biol 2002;26:587-593.
47. De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996;153:633-637.
48. Engelen MPKJ, Schols AMWJ, Heidendal GAK, Wouters EFM. Dual-energy X-ray absorptiometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 1998;68:1298-1303.
49. Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS. Declining bone mass in men with chronic pulmonary disease. Chest 1999;116: 1616-1624.
50. Espat NJ, Moldawer LL, Copeland EM. Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachetic cancer patients. J Surg Oncol 1995;58:77-82.
51. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coates AJS. Loss of bone mineral in patients with cachexia due to chroic heart failure. Am J Cardiol 1999;83:612-615.
52. Ionescu AA, Evans WD, Pettit RJ, Nixon LS, Stone MD, Shale DJ. Hidden depletion of fat-free mass and bone mineral density in adults with cystic fibrosis. Chest 2003;124:2220-2228.
53. Bertolini DR, Nedwin GE, Bingman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factor. Nature 1986;319:516-518.
54. Gowen M, Mundy GR. Actions of recombinant interleukin 1, interleukin 2 and interferon γ on bone resorption in vitro. J Immunol 1986; 136:2478-2482.
55. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988;318:818-828.
56. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling. N Engl J Med 1995;332:305-311.
57. Neale SD, Schulze E, Smith R, Athanasou NA. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease. QJM 2002;95:233-240.
58. Scottish Intercollegiate Guidelines Network. Management of osteoporosis: a national clinical guideline. Available at www.sign.ac.uk (accessed October 2004).
59. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59:1-232.
60. Creutzberg EC, Schols AMWJ, Weling-Scheepers CAPM, Buurman WA, Wouters EFM. Characterization of nonresponse to high calorie oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:745-752.
61. Melton L, Orwoll E, Wasnich R. Does bone density predict fractures comparably in men and women? Osteoporos Int 2001;12:707-709.
62. Coupland C, Cliffe S, Bassey E, Grainge M, Hosking D, Chilvers C. Habitual physical activity and bone mineral density in postmenopausal women in England. Int J Epidemiol 1999;28:241-246.
63. Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity and body mass index. J Bone Miner Res 2000;15:322-331.
64. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:855-859.